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General procedure for the alkylation of aldehydes with allenamides
Method A (racemic protocol):
To a solution of Ph 3 PAuNTf 2 (2:1) toluene adduct (12,55 mg, 0.008 mmol), 2,2'-bipyridine (4.99 mg, 0.032 mmol) and benzoic acid (3.90 mg, 0.032 mmol) in Toluene (0.5 ml) in a dried Schlenk tube, was sequentially added a solution of the corresponding aldehyde 2 (0.320 mmol) and pyrrolidine (3.97 µl, 0.048 mmol) in Toluene (0.5 ml) and another of the corresponding allenamide 1 (0.160 mmol) in Toluene (0.5 ml; dropwise addition). The mixture was stirred under Argon atmospher at 60 ºC until the allenamide was consumed (the progress of the reaction was easily monitored by tlc) and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl 3 for 1 H-NMR analysis. The crude mixture was then purified on column chromatography (hexanes/EtOAc 10-40%). All the reported yields are isolated yields.
Method A´ (racemic protocol followed by in situ reduction with NaBH 4 ):
Same conditions than Method A but once the allenamide was consumed (the progress of the reaction was easily monitored by tlc) the reaction was quenched by the addition of a solution of NaBH 4 (24.21 mg, 0.640 mmol) in MeOH (2 mL), stirred for 30 minutes and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl 3 for 1 H-NMR analysis.
The crude mixture was purified on column chromatography (hexanes / EtOAc 40-80% and 10% DCM). All the reported yields are isolated yields.
Method B (asymmetric protocol):
To a solution of IPrAuNTf 2 (13.84 mg, 0.016 mmol), 2,2'-bipyridine (4.99 mg, 0.032 mmol) and benzoic acid (3.90 mg, 0.032 mmol) in Toluene (0.5 ml) in a dried Schlenk tube, was sequentially added a solution of the corresponding aldehyde 2 (0.320 mmol) and chiral organocatalyst (0.032 mmol) in Toluene (0.5 ml) and another solution of the corresponding allenamide 1 (0.160 mmol) in Toluene (0.5 ml; dropwise adition). The mixture was stirred under Argon atmospher at 60 ºC until all the allenamide was consumed (the progress of the reaction was easily monitored by tlc) and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl 3 for 1 H-NMR analysis. The crude mixture was then purified on column chromatography (hexanes/EtOAc 10-40%). All the reported yields are isolated yields.
Method B´(asymmetric protocol followed by in situ reduction with NaBH 4 ): Same conditions than Method B but once the allenamide was consumed (the progress of the reaction was easily monitored by tlc) the reaction was quenched with the addition of a solution of NaBH 4 (24.21 mg, 0.640 mmol) in MeOH (2 mL), stirred for 30 minutes and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl 3 for 1 H-NMR analysis. The crude mixture was purified on column chromatography (hexanes/EtOAc 40-80% and 10% DCM). All the reported yields are isolated yields.
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Characterization data (E)-2-Methyl-5-(2-oxooxazolidin-3-yl)-2-phenylpent-4-enal (3aa) Racemic sample: Table 3 , entry 5; ee = 72%: Table 3 , entry 6; ee = 75%: Table 3 , entry 7; ee = 81%: 
(E)-N-Benzyl-N-(5-hydroxy-4-methyl-4-phenylpent-1-en-1-yl)-4-methylbenzenesulfonamide (3da´)
Method A´: 51% yield. Method B´: 50% yield (80% ee). 
